Iron and reactive oxygen species: Friends or foes of cancer cells?

Antioxidants and Redox Signaling

Volumn 20, Issue 12, 2014, Pages 1917-1924

  Bystrom, Laura M ^a   Guzman, Monica L ^a   Rivella, Stefano ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; IRON; IRON CHELATING AGENT; REACTIVE OXYGEN METABOLITE; TUMOR PROMOTER;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER CHEMOTHERAPY; CARCINOGENESIS; CELL METABOLISM; HOMEOSTASIS; HUMAN; IRON DEPLETION; IRON METABOLISM; NEOPLASM; NONHUMAN; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; STRUCTURE ACTIVITY RELATION; METABOLISM; PATHOLOGY;

HUMANS; IRON; NEOPLASMS; REACTIVE OXYGEN SPECIES;

EID: 84897038642     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2012.5014     Document Type: Review

References (50)

1. Andrews NC. Iron homeostasis: Insights from genetics and animal models. Nat Rev Genet 1: 208-217, 2000
2. Balaban RS, Nemoto S, and Finkel T. Mitochondria, oxidants, and aging. Cell 120: 483-495, 2005
3. Benassi B, Fanciulli M, Fiorentino F, Porrello A, Chiorino G, Loda M, Zupi G, and Biroccio A. c-Myc phosphorylation is required for cellular response to oxidative stress. Mol Cell 21: 509-519, 2006
4. Benhar M, Engelberg D, and Levitzki A. ROS, stressactivated kinases and stress signaling in cancer. EMBO Rep 3: 420-425, 2002
5. Burch PM and Heintz NH. Redox regulation of cell-cycle reentry: Cyclin D1 as a primary target for the mitogenic effects of reactive oxygen and nitrogen species. Antioxid Redox Signal 7: 741-751, 2005
6. Callens C, Coulon S, Naudin J, Radford-Weiss I, Boissel N, Raffoux E, Wang PH, Agarwal S, Tamouza H, Paubelle E, Asnafi V, Ribeil JA, Dessen P, Canioni D, Chandesris O, Rubio MT, Beaumont C, Benhamou M, Dombret H, Macintyre E, Monteiro RC, Moura IC, and Hermine O. Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. J Exp Med 207: 731-750, 2010
7. Chaston TB, Watts RN, Yuan J, and Richardson DR. Potent antitumor activity of novel iron chelators derived from di-2-pyridylketone isonicotinoyl hydrazone involves fentonderived free radical generation. Clin Cancer Res 10: 7365-7374, 2004
8. Coffman LG, Parsonage D, D'Agostino R, Jr., Torti FM, and Torti SV. Regulatory effects of ferritin on angiogenesis. Proc Natl Acad Sci U S A 106: 570-575, 2009
9. D'Autreaux B and Toledano MB. ROS as signalling molecules: Mechanisms that generate specificity in ROS homeostasis. Nat Rev Mol Cell Biol 8: 813-824, 2007
10. Daniels TR, Delgado T, Helguera G, and Penichet ML. The transferrin receptor part II: Targeted delivery of therapeutic agents into cancer cells. Clin Immunol 121: 159-176, 2006
11. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, Joshua B, Kaplan MJ, Wapnir I, Dirbas FM, Somlo G, Garberoglio C, Paz B, Shen J, Lau SK, Quake SR, Brown JM, Weissman IL, and Clarke MF. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458: 780-783, 2009
12. Fleming MD, Romano MA, Su MA, Garrick LM, Garrick MD, and Andrews NC. Nramp2 is mutated in the anemic Belgrade (b) rat: Evidence of a role for Nramp2 in endosomal iron transport. Proc Natl Acad Sci U S A 95: 1148-1153, 1998
13. Ganz T and Nemeth E. The hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disorders. Hematology Am Soc Hematol Educ Program 2011: 538-542, 2011
14. Gardenghi S, Ramos P, Marongiu MF, Melchiori L, Breda L, Guy E, Muirhead K, Rao N, Roy CN, Andrews NC, Nemeth E, Follenzi A, An X, Mohandas N, Ginzburg Y, Rachmilewitz EA, Giardina PJ, Grady RW, and Rivella S. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in beta-Thalassemic mice. J Clin Invest 120: 4466-4477, 2010
15. Ghaffari S. Oxidative stress in the regulation of normal and neoplastic hematopoiesis. Antioxid Redox Signal 10: 1923-1940, 2008
16. Gkouvatsos K, Papanikolaou G, and Pantopoulos K. Regulation of iron transport and the role of transferrin. Biochim Biophys Acta 1820: 188-202, 2012
17. Guo M, Perez C, Wei Y, Rapoza E, Su G, Bou-Abdallah F, and Chasteen ND. Iron-binding properties of plant phenolics and cranberry's bio-effects. Dalton Trans 4951-4961, 2007
18. Guzman ML, Rossi RM, Karnischky L, Li X, Peterson DR, Howard DS, and Jordan CT. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 105: 4163-4169, 2005
19. Habashy HO, Powe DG, Staka CM, Rakha EA, Ball G, Green AR, Aleskandarany M, Paish EC, Douglas Macmillan R, Nicholson RI, Ellis IO, and Gee JM. Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen. Breast Cancer Res Treat 119: 283-293, 2010
20. Halliwell B. Are polyphenols antioxidants or pro-oxidants?What do we learn from cell culture and in vivo studies?Arch Biochem Biophys 476: 107-112, 2008
21. Kalinowski DS and Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev 57: 547-583, 2005
22. Kalinowski DS and Richardson DR. Future of toxicology-iron chelators and differing modes of action and toxicity: The changing face of iron chelation therapy. Chem Res Toxicol 20: 715-720, 2007
23. Kim KK, Singh AP, Singh RK, Demartino A, Brard L, Vorsa N, Lange TS, and Moore RG. Anti-Angiogenic activity of cranberry proanthocyanidins and cytotoxic properties in ovarian cancer cells. Int J Oncol 40: 227-235, 2012
24. Krause A, Neitz S, Magert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, and Adermann K. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett 480: 147-150, 2000
25. Krotz F, Sohn HY, and Pohl U. Reactive oxygen species: Players in the platelet game. Arterioscler Thromb Vasc Biol 24: 1988-1996, 2004
26. Lehtinen MK, Yuan Z, Boag PR, Yang Y, Villen J, Becker EB, DiBacco S, de la Iglesia N, Gygi S, Blackwell TK, and Bonni A. A conserved MST-FOXO signaling pathway mediates oxidative-stress responses and extends life span. Cell 125: 987-1001, 2006
27. Li L, Fang CJ, Ryan JC, Niemi EC, Lebron JA, Bjorkman PJ, Arase H, Torti FM, Torti SV, Nakamura MC, and Seaman WE. Binding and uptake of H-ferritin are mediated by human transferrin receptor-1. Proc Natl Acad Sci U S A 107: 3505-3510, 2010
28. Li Q and Engelhardt JF. Interleukin-1beta induction of NFkappaB is partially regulated by H2O2-mediated activation of NFkappaB-inducing kinase. J Biol Chem 281: 1495-1505, 2006
29. Lu HF, Hsueh SC, Ho YT, Kao MC, Yang JS, Chiu TH, Huamg SY, Lin CC, and Chung JG. ROS mediates baicalininduced apoptosis in human promyelocytic leukemia HL-60 cells through the expression of the Gadd153 and mitochondrial-dependent pathway. Anticancer Res 27: 117-125, 2007
30. Miret S, Simpson RJ, and McKie AT. Physiology and molecular biology of dietary iron absorption. Annu Rev Nutr 23: 283-301, 2003
31. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, and Kaplan J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306: 2090-2093, 2004
32. Ohgami RS, Campagna DR, McDonald A, and Fleming MD. The Steap proteins are metalloreductases. Blood 108: 1388-1394, 2006
33. Park CH, Valore EV, Waring AJ, and Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 276: 7806-7810, 2001
34. Pelicano H, Carney D, and Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 7: 97-110, 2004
35. Perez CA, Wei Y, and Guo M. Iron-binding and anti-Fenton properties of baicalein and baicalin. J Inorg Biochem 103: 326-332, 2009
36. Pinnix ZK, Miller LD, Wang W, D'Agostino R, Jr., Kute T, Willingham MC, Hatcher H, Tesfay L, Sui G, Di X, Torti SV, and Torti FM. Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med 2: 43ra56, 2010
37. Raj L, Ide T, Gurkar AU, Foley M, Schenone M, Li X, Tolliday NJ, Golub TR, Carr SA, Shamji AF, Stern AM, Mandinova A, Schreiber SL, and Lee SW. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 475: 231-234, 2011
38. RichardsonDR,KalinowskiDS, Lau S, Jansson PJ, and Lovejoy DB. Cancer cell iron metabolism and the development of potent iron chelators as anti-Tumour agents. Biochim Biophys Acta 1790: 702-717, 2009
39. Salganik RI. The benefits and hazards of antioxidants: Controlling apoptosis and other protective mechanisms in cancer patients and the human population. J Am Coll Nutr 20: 464S-472S; discussion 473S-475S, 2001
40. Sarkar FH and Li Y. NF-kappaB: A potential target for cancer chemoprevention and therapy. Front Biosci 13: 2950-2959, 2008
41. Singh AP, Lange TS, Kim KK, Brard L, Horan T, Moore RG, Vorsa N, and Singh RK. Purified cranberry proanthocyanidines (PAC-1A) cause pro-Apoptotic signaling, ROS generation, cyclophosphamide retention and cytotoxicity in high-risk neuroblastoma cells. Int J Oncol 40: 99-108, 2012
42. Smith J, Ladi E, Mayer-Proschel M, and Noble M. Redox state is a central modulator of the balance between self-renewal and differentiation in a dividing glial precursor cell. Proc Natl Acad Sci U S A 97: 10032-10037, 2000
43. Snyder CM and Chandel NS. Mitochondrial regulation of cell survival and death during low-oxygen conditions. Antioxid Redox Signal 11: 2673-2683, 2009
44. Torti SV and Torti FM. Ironing out cancer. Cancer Res 71: 1511-1514, 2011
45. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, Chiao PJ, Achanta G, Arlinghaus RB, Liu J, and Huang P. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 10: 241-252, 2006
46. Vidal S, Belouchi AM, Cellier M, Beatty B, and Gros P. Cloning and characterization of a second human NRAMP gene on chromosome 12q13. Mamm Genome 6: 224-230, 1995
47. Weinberg ED. The role of iron in cancer. Eur J Cancer Prev 5: 19-36, 1996
48. Wu LJ, Leenders AG, Cooperman S,Meyron-Holtz E, Smith S, Land W, Tsai RY, Berger UV, Sheng ZH, and Rouault TA. Expression of the iron transporter ferroportin in synaptic vesicles and the blood-brain barrier. Brain Res 1001: 108-117, 2004
49. Wu XJ and Hua X. Targeting ROS: Selective killing of cancer cells by a cruciferous vegetable derived pro-oxidant compound. Cancer Biol Ther 6: 646-647, 2007
50. Yalcin S, Marinkovic D, Mungamuri SK, Zhang X, Tong W, Sellers R, and Ghaffari S. ROS-mediated amplification of AKT/mTOR signalling pathway leads to myeloproliferative syndrome in Foxo3 (-/-) mice. EMBO J 29: 4118-4131, 2010.